News from the FDA/CDC

FDA: PrEP indication updated to include adolescents at risk of HIV infection

Publish date: May 17, 2018

 


2.2 HIV-1 screening for individuals receiving Truvada for HIV-1 PrEP

Screen all patients for HIV-1 infection before initiating Truvada for HIV-1 PrEP and at least once every 3 months while taking Truvada

2.5 Recommended dosage for HIV-1 PrEP

The dosage of Truvada in HIV-1 uninfected adults and adolescents weighing at least 35 kg is one tablet (containing 200 mg of FTC and 300 mg of TDF) once daily taken orally with or without food.

Pages

Recommended Reading

Medical marijuana’s ‘Catch-22’: Federal limits on research hinder patients’ relief
MDedge Infectious Disease
Comorbidity occurs earlier and more commonly with HIV infection
MDedge Infectious Disease
Antiretroviral choice for pregnant women with HIV does not appear to impact birth outcomes
MDedge Infectious Disease
HIV infection linked to higher risk of non-melanoma skin cancer
MDedge Infectious Disease
Most HIV patients need treatment for acute HCV
MDedge Infectious Disease
New trial to assess HIV+/HIV+ kidney transplants
MDedge Infectious Disease
Emotional regulation training lowers risk of adolescents having sex
MDedge Infectious Disease
Make the Diagnosis - May 2018
MDedge Infectious Disease
FDA seeks comments on pediatric HIV product development
MDedge Infectious Disease
FDA approves epoetin alfa biosimilar to treat anemia
MDedge Infectious Disease